Skip to main content

DAVITA INC.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

DVA$191.35-1.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Consolidated Statements of Income for the three and six months ended June 30, 2026 and June 30, 2025

CONSOLIDATED STATEMENTS OF INCOME

Three months ended June 30,Six months ended June 30,
2026202520262025
Dialysis patient service revenues$3,366,377$3,206,871$6,639,174$6,309,864
Other revenues187,707172,655330,458293,191
Total revenues3,554,0843,379,5266,969,6326,603,055
Operating expenses:
Patient care costs2,392,0012,261,5404,734,2584,501,200
General and administrative423,458412,805845,372786,895
Depreciation and amortization167,808174,704345,637351,155
Equity investment income, net(8,184)(7,364)(16,528)(12,973)
Total operating expenses2,975,0832,841,6855,908,7395,626,277
Operating income579,001537,8411,060,893976,778
Debt expense(150,256)(146,062)(295,387)(281,117)
Debt extinguishment and modification costs(2,035)—(2,035)—
Other income (loss), net8,300(22,851)12,773(40,400)
Income before income taxes435,010368,928776,244655,261
Income tax expense91,78793,708157,986147,825
Net income343,223275,220618,258507,436
Less: Net income attributable to noncontrolling interests(77,826)(75,883)(155,331)(145,182)
Net income attributable to DaVita Inc.$265,397$199,337$462,927$362,254
Earnings per share attributable to DaVita Inc.:
Basic net income$4.10$2.62$7.01$4.67
Diluted net income$4.02$2.58$6.86$4.57
Weighted average shares for earnings per share:
Basic shares64,78175,94366,07877,646
Diluted shares66,09277,36267,47679,309
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.